Literature DB >> 7588568

Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: purification of the recombinant proteins and generation of polyclonal antibodies in chicken.

V Magdolen1, P Rettenberger, A Lopens, H Oi, F Lottspeich, J Kellermann, S Creutzburg, L Goretzki, U H Weidle, O Wilhelm.   

Abstract

The receptor for urokinase-type plasminogen activator (uPAR) may contribute to the invasive and metastatic capacity of tumor cells by focusing the serine protease urokinase-type plasminogen activator (uPA) to the cell surface. uPA activates plasminogen to plasmin which in turn degrades extracellular matrix proteins or activates other proteases. Mature uPAR is a heavily glycosylated protein of about 284 amino acids attached to the plasma membrane via a glycosyl-phosphatidylinositol (GPI) anchor. A set of different polyclonal uPAR antibodies has been generated in order to investigate the role of uPAR in tumor spreading in more detail. For this purpose, uPAR (lacking the GPI anchor) was expressed in E. coli and Chinese hamster ovary (CHO) cells. Recombinant uPAR from E. coli (corresponding to amino acids 1-284 of human uPAR) was expressed with an N-terminal histidine-tag insertion and purified by nickel chelate affinity chromatography. Soluble uPAR, synthesized by CHO cells (corresponding to amino acids 1-277 of human uPAR), was isolated by ligand (uPA) affinity chromatography. Expression in E. coli led to a nonglycosylated form of uPAR, whereas uPAR produced by CHO cells seemed to be glycosylated to a similar extent as the naturally occurring human form of uPAR (as analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis). Prior to immunization the N-termini of the recombinant uPAR variants were determined by amino acid sequence analysis. Polyclonal antibodies were generated in chickens and purified from egg yolk. The reaction patterns of these antibodies were analyzed by Western blot analyses and flow cytofluorometry.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7588568     DOI: 10.1002/elps.11501601134

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  6 in total

1.  Dissecting mannose 6-phosphate-insulin-like growth factor 2 receptor complexes that control activation and uptake of plasminogen in cells.

Authors:  Vladimir Leksa; Karin Pfisterer; Gabriela Ondrovičová; Brigitte Binder; Silvia Lakatošová; Clemens Donner; Herbert B Schiller; Alexander Zwirzitz; Katarína Mrvová; Vladimir Pevala; Eva Kutejová; Hannes Stockinger
Journal:  J Biol Chem       Date:  2012-05-21       Impact factor: 5.157

2.  Lactoferrin is a natural inhibitor of plasminogen activation.

Authors:  Alexander Zwirzitz; Michael Reiter; Rostislav Skrabana; Anna Ohradanova-Repic; Otto Majdic; Marianna Gutekova; Ondrej Cehlar; Eva Petrovčíková; Eva Kutejova; Gerold Stanek; Hannes Stockinger; Vladimir Leksa
Journal:  J Biol Chem       Date:  2018-04-18       Impact factor: 5.157

3.  Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.

Authors:  T Luther; V Magdolen; S Albrecht; M Kasper; C Riemer; H Kessler; H Graeff; M Müller; M Schmitt
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

4.  Production and functional characterization of a soluble recombinant form of mouse CD59.

Authors:  N K Rushmere; C W Van Den Berg; B P Morgan
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

5.  Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group.

Authors:  Ralf Hildenbrand; Marco Niedergethmann; Alexander Marx; Djeda Belharazem; Heike Allgayer; Christiane Schleger; Philipp Ströbel
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

6.  Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue.

Authors:  R Hildenbrand; N Arens
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.